Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant
Call scheduled for 8:30 a.m. Eastern Time on June 24 to review results of successful Phase 2b trial showing achievement of primary and secondary endpoints with potential first-in-class specific orexin-2 receptor antagonist for the treatment of insomnia
- Key Opinion Leaders, Dr. Thomas Roth and Dr. David Kupfer, to be joined by Dr. Remy Luthringer, Executive Chairman and CEO of Minerva
WALTHAM, Mass., June 23, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, will host a live conference call and webcast tomorrow, June 24, 2019 to discuss the results of its successful Phase 2b clinical trial of seltorexant (MIN-202) in patients with insomnia disorder (see dial-in information below). The Company plans to issue a press release detailing top-line results prior to the call.
Conference Call Information:
Minerva Neurosciences will hold a conference call and live audio webcast on June 24, 2019 at 8:30 a.m. Eastern Time to discuss the results of this trial. To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 1644578. To access the webcast, please go to https://engage.vevent.com/rt/minervaneurosciencesinc~062419.
The live webcast can also be accessed under “Events and Presentations” in the Investors and Media section of Minerva’s website at ir.minervaneurosciences.com. The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.
Key Opinion Leaders:
Dr. Thomas Roth
Thomas Roth, Ph.D., founded the Sleep Disorders and Research Center at the Henry Ford Hospital in Detroit, Michigan in 1978 and has since served as Director of the Center. Dr. Roth is also a Professor in the Department of Psychiatry at Wayne State University School of Medicine in Detroit, and serves as a Clinical Professor in the Department of Psychiatry at the University of Michigan’s College of Medicine in Ann Arbor.
Dr. Roth primarily publishes on the epidemiology, pathophysiology, diagnosis, comorbidity with other disorders, and treatment of insomnia. His research focuses on sleep loss, sleep fragmentation, and deviation from sleep processes, including pharmacological effects and sleep pathologies.
After serving as President of the Sleep Research Society and the Founding President of the National Sleep Foundation (NSF), Dr. Roth became Chairman of the National Center on Sleep Disorders Research Advisory Board at the National Institute of Health. He has also served on the Board of Directors of the Associated Professional Sleep Societies (APSS).
In 2002, Dr. Roth received the NSF’s Lifetime Achievement Award for his accomplishments and contributions to sleep science, sleep medicine, and public health. He also received a Distinguished Research Award from the Sleep Research Society as well as the Nathanial Kleitman Award from the Academy of Sleep Medicine.
Dr. Roth is the past Editor-in-Chief of the journal Sleep. He currently sits on the editorial boards of Sleep Reviews, Stress Medicine, Advances in Therapy, and Human Psychopharmacology. Dr. Roth has published over 525 manuscripts, 13 edited volumes, 250 chapters, and 621 abstracts.
Dr. David Kupfer
David J. Kupfer, M.D., is Distinguished Professor Emeritus, Department of Psychiatry, University of Pittsburgh School of Medicine, and a board member of Minerva Neurosciences. He received his bachelor’s and M.D. degrees from Yale University. Following completion of an internship, Dr. Kupfer continued his postgraduate clinical and research training at the Yale New Haven Hospital and the National Institute of Mental Health (NIMH). In 1970, he was appointed Assistant Professor of Psychiatry at Yale University School of Medicine. Dr. Kupfer joined the faculty at the University of Pittsburgh in 1973.
From 1983 to 2009, Dr. Kupfer served as Chair of the Department of Psychiatry at the University of Pittsburgh School of Medicine, and Director of Research at Western Psychiatric Institute and Clinic. Under Dr. Kupfer's direction, WPIC became one of the nation's preeminent university-based psychiatric research centers.
Dr. Kupfer's own research has focused primarily on sleep physiology, on long-term treatment strategies for recurrent mood disorders, and on the relationship between biomarkers and depression. A prolific writer, Dr. Kupfer has authored or co-authored a combination of more than 1,000 articles, books, and book chapters, principally focused on sleep and mood disorders.
He is internationally recognized for his role as Chair of the American Psychiatric Association Task Force for DSM-5. In recognition of his contributions to the field, Dr. Kupfer has been the recipient of numerous awards and honors from professional societies. In 1990, he was elected to the National Academy of Medicine (formerly the Institute of Medicine).
About Seltorexant (MIN-202)
Seltorexant is a selective orexin-2 receptor antagonist under co-development by Janssen Pharmaceutica N.V., a Pharmaceutical Company of Johnson & Johnson, and Minerva as adjunctive therapy for Major Depressive Disorder (MDD) and for the treatment of insomnia disorder. The orexin system in the brain is involved in the control of several key functions, including metabolism, stress response and wakefulness. This system promotes arousal (wakefulness) and is hypothesized to play a role in excessive arousal, which occurs in patients with insomnia and in subsets of patients with mood disorders, and to have clinical utility in the treatment of such patients.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit http://www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and scope of current clinical trials and results of clinical trials with roluperidone, seltorexant, MIN-117 and MIN-301; the timing and scope of future clinical trials and results of clinical trials with these compounds; the clinical and therapeutic potential of these compounds; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management’s ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, filed with the Securities and Exchange Commission on May 6, 2019. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
FRO - Invitation to Q3 2019 Results Conference Call and Webcast19.11.2019 13:16:00 CET | Press release
Frontline Ltd.’s preliminary third quarter 2019 results will be released on Wednesday November 27 2019, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at www.frontline.bm ahead of the conference call. In order to attend the conference call you may do one of the following: a. Webcast Go to the Investor Relations section at www.frontline.bm and follow the “Webcast” link. b. Conference Call Participant dial-in telephone numbers: Norway +47 2156 3162 Norway toll free 800 10392 UK +44 (0) 203 009 5710 UK Toll Free 0 800 376 7425 USA +1 917 720 0178 USA Toll Free 866 869 2321 Conference ID 5598374 Participants will be asked for their full name & Conference ID. A Q&A session will be held after the teleconference/webcast. Information on how to submit questions will be given at the beginning of the session. The presentation material which will be used in th
Oasmia offentliggör prospekt i samband med företrädesemission om cirka 399 MSEK samt uppdaterad information som återfinns i prospektet19.11.2019 13:00:00 CET | Pressemelding
EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER ÄN VAD SOM FÖLJER AV SVENSK RÄTT. Styrelsen i Oasmia Pharmaceutical AB (“Oasmia” eller ”Bolaget”) meddelande den 11 november 2019 om genomförandet av en nyemission av aktier med företrädesrätt för Oasmias befintliga aktieägare om cirka 399 MSEK ("Företrädesemissionen"). Bolaget har med anledning av Företrädesemissionen upprättat ett prospekt som idag godkänts och registrerats av Finansinspektionen. Offentliggörande av prospekt För fullständig information om Företrädesemissionen hänvisas till det prospekt som upprättats av Bolaget samt idag godkänts och registrerats av Finansinspektionen per dagens datum.
Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus19.11.2019 13:00:00 CET | Press release
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Oasmia Pharmaceuticals AB (publ). See the section “IMPORTANT INFORMATION” below. The board of Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) announced on 11 November 2019 to carry out a new issue of shares with preferential rights for Oasmia’s shareholders of approximately SEK 399 million (the “Rights Issue”). As a result of the Rights Issue, the Company has prepared a prospectus, which has been approved and registered by the Swedish Financial Supervisory Authority today. Publication of the prospectus For complete information on the Rights Issue, refer to the prospectus that has been prepared by Oasmia as well as appro
Medtronic Reports Second Quarter Financial Results19.11.2019 12:45:00 CET | Press release
Revenue of $7.7 Billion Increased 3.0% Reported and 4.1% Organic GAAP Diluted EPS of $1.01; Non-GAAP Diluted EPS of $1.31 Cash Flow from Operations of $1.9 Billion Grew 61%; Free Cash Flow of $1.6 Billion Grew 66% Company Raises FY20 EPS Guidance DUBLIN, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2020, which ended October 25, 2019. The company reported second quarter worldwide revenue of $7.706 billion, an increase of 3.0 percent as reported or 4.1 percent on an organic basis, which adjusts for a $97 million negative impact from foreign currency and a $16 million contribution from the company’s acquisition of Titan Spine, which is reported in the Spine division in the Restorative Therapies Group. As reported, second quarter GAAP net income and diluted earnings per share (EPS) were $1.364 billion and $1.01, respectively. As detailed in the financial schedules included through the link at the end of t
Avenir LNG collaborates with Golar Power on developing small-scale LNG distribution in Brazil19.11.2019 12:00:00 CET | Press release
London, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Avenir LNG Limited (“Avenir”) wishes to announce that it will collaborate with Golar Power Limited (“Golar Power”) in developing the small-scale LNG market in Brazil. Avenir’s second 7,500 cbm LNG Carrier will be used to deliver LNG to various ports across Brazil upon delivery. The vessel will also offer ship-to-ship bunkering capability as part of Avenir’s global multi-nodal bunkering solution; adding to the Colombian, Mediterranean and Malaysian nodes which the company currently offers. Commenting on the collaboration with Golar Power, Andrew Pickering, Chief Executive Officer of Avenir LNG Limited, said, “This is another step in our strategy where we are working closely with a shareholder in leveraging its FSRU platform to develop small-scale LNG distribution and bunkering in key developing markets.” Commenting on the collaboration with Avenir LNG, Eduardo Antonello, Chief Executive Officer of Golar Power Limited, said, “Accessing small-scal
Conversion factor for Exchange offer in SGB IL 3102 2019-11-1919.11.2019 11:03:00 CET | Press release
2019-11-19 Conversion factor SGB IL 3102/3109; 0.8381954 The conversion factor of SGB IL 3102/3109 indicates the amount of SGB IL 3102 that the SNDO will buy back for each SGB IL 3109 issued in the switch auction at November 19, 2019. For further information, please contact: The funding desk + 46 8 613 4780 Funding@riksgalden.se